health risks of semaglutide Who Should Consider GLP-1? Semaglutide GLP-1 is generally recommended for individuals with type 2 diabetes who have not achieved adequate blood sugar control with other medications such as metformin, or for The FDA Warns of the

New England Journal of Medicine: GLP-1 Receptor Agonists , a comprehensive review of GLP-1 receptor agonist pharmacology, clinical outcomes, and emerging therapeutic applications from one of the most respected medical journals in the world

A holistic approach includes dietary modifications, high-quality supplementation, lifestyle interventions, and stress management to support long-term health and prevent complications

Rebound Risks : Weight regain common post-semaglutide due to increased appetite and fat production

or serving on advisory boards for AbbVie, Acadia, Allergan, the Alzheimers Association, Axovant, AZTherapies, Biogen, Eisai, Grifols, Harvard Medical School Graduate Continuing Education, JOMDD, Lundbeck, Merck, Novo Nordisk, ONO, Prothena, Qynapse, Roche/Genentech, Sunovion, Suven, and Synexus